Molecular Profiling Protocol (SCRI-CA-001)

This study has been completed.
Sponsor:
Collaborator:
Translational Genomics Research Institute, Phoenix, Arizona.
Information provided by:
Scottsdale Healthcare
ClinicalTrials.gov Identifier:
NCT00530192
First received: September 14, 2007
Last updated: July 9, 2009
Last verified: July 2009
  Purpose

This is an open-label, multicenter pilot study in patients with advanced solid tumors.

The primary objective of this study is to compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on.

To be eligible, patients must have received at least two lines of prior chemotherapeutic, hormonal or biological regimens for advanced disease, have measurable or evaluable, refractory disease and have clear documentation of the time between treatment start and documented progression on the last treatment prior to study entry. Eligible patients must undergo or have available a tumor biopsy for molecular profiling within 2 months of IHC/FISH and/or DNA microarray analysis.


Condition Intervention Phase
Refractory Cancer
Other: Treatment based on Molecular Profiling
Phase 0

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

Resource links provided by NLM:


Further study details as provided by Scottsdale Healthcare:

Primary Outcome Measures:
  • To compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on. [ Time Frame: Every 8 weeks disease assessments are performed ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine the frequency with which molecular profiling of a patient's tumor by IHC/FISH and/or microarray analysis yields a target against which there is a commercially available, approved therapeutic regimen. [ Time Frame: Time of Profiling- Baseline ]
  • To determine the response rate (according to RECIST or disease-specific response criteria) and the percent of patients with non-progression at 4 months in patients with solid tumors whose therapy is selected by molecular profiling. [ Time Frame: 4 months ]

Enrollment: 86
Study Start Date: September 2006
Estimated Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Treatment based on Molecular Profiling
    Treatment with commercially available treatments (per package insert instructions)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic cancer which has progressed on 2 prior chemotherapeutic, hormonal or biological regimens for advanced disease.
  • Be defined as refractory to the last line of therapy
  • Have documentation of the best clinical response to the treatment regimen immediately prior to entering this study

Exclusion Criteria:

  • Patients with symptomatic CNS metastasis
  • Any previous history of another malignancy within 5 years of study entry
  • Uncontrolled intercurrent illness
  • Known HIV, HBV, HCV infection
  • Pregnant or breast-feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00530192

Locations
United States, Alabama
Oncology Specialties
Huntsville, Alabama, United States, 35805
United States, Arizona
TGen Clinical Research Services
Scottsdale, Arizona, United States, 85258
Mayo Clinic
Scottsdale, Arizona, United States, 85259
United States, California
Tower Oncology
Beverly Hills, California, United States, 90211
Louis Warschaw Prostate Cancer Center at Cedars Sinai Medical Center
Los Angeles, California, United States, 90048
United States, Indiana
Central Indiana Cancer Center
Indianapolis, Indiana, United States, 46227
United States, South Carolina
Cancer Center of the Carolinas
Greenville, South Carolina, United States, 29605
United States, Texas
South Texas Oncology Hematology
San Antonio, Texas, United States, 78229
Tyler Cancer Center
Tyler, Texas, United States, 75702
Sponsors and Collaborators
Scottsdale Healthcare
Translational Genomics Research Institute, Phoenix, Arizona.
Investigators
Principal Investigator: Daniel D Von Hoff, MD TGen Clinical Research Services at Scottsdale Healthcare
  More Information

No publications provided

Responsible Party: Scottsdale Healthcare
ClinicalTrials.gov Identifier: NCT00530192     History of Changes
Other Study ID Numbers: SCRI-CA-001, SCRI-CA-001
Study First Received: September 14, 2007
Last Updated: July 9, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Scottsdale Healthcare:
Refractory Cancer
Molecular Profile

ClinicalTrials.gov processed this record on July 23, 2014